Literature DB >> 18704294

The expression and activity of MMPs are increased in residual tumor tissues after the termination of immunotherapy.

Ting Xiong1, Huimin Peng, Guoxi Chen, Ye Yuan.   

Abstract

To investigate the invasive ability of the residual tumor cells after immunotherapy and explore the feasible approach suppressing the invasion, mice were inoculated with B16 cells, and then treated by gene therapy with p4-1BBL/psPD-1 or IFN-gamma. The production and activities of MMP-9 and MMP-2 in residual tumor tissues were analyzed with gelatin zymography 1 day and 7 days after the termination of the immunotherapy. The production of MMP-9 and MMP-2 by B16 cells treated with IFN-gamma was also analyzed. IFN-gamma-treated B16 cells were inoculated to mice via subcutaneous injection. The invasion of tumor to muscular tissue was analyzed. Gene therapy with CH50 was used to suppress the invasive growth of tumor. The results showed that the expression and the activities of MMP-9 and MMP-2 were significantly increased 7 days after the end of immunotherapy. The response of tumor cells to ECM molecules was intensified after the removal of IFN-gamma, resulting in significant increase of both the production and activities of MMP-9 and MMP-2, and the increased invasion of tumor. Gene therapy with CH50 effectively suppressed the invasive growth of tumor. It is concluded that the termination of immunotherapy may result in a higher metastatic potential of residual tumor cells. Suppressing tumor invasion by suitable treatment will improve the efficacy of immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18704294     DOI: 10.1007/s11596-008-0401-5

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  17 in total

1.  [Correlation between expression of MMP-2, MMP-9, TIMP-2, TIMP-1 and metastasis of neuroblastoma].

Authors:  Yu Cheng; Qian Dong; Li-rong Sun; Chuan-min Yang; Bu-xian Jiang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2005-03

2.  IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk.

Authors:  M Strasly; F Cavallo; M Geuna; S Mitola; M P Colombo; G Forni; F Bussolino
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

3.  Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy.

Authors:  Yu-Fei He; Xiao-Hong Wang; Gui-Mei Zhang; Hong-Tao Chen; Hui Zhang; Zuo-Hua Feng
Journal:  Cancer Immunol Immunother       Date:  2005-03-18       Impact factor: 6.968

4.  Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.

Authors:  Zoya R Yurkovetsky; Galina V Shurin; Denise A Barry; Andre C Schuh; Michael R Shurin; Paul D Robbins
Journal:  J Gene Med       Date:  2006-02       Impact factor: 4.565

5.  Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma.

Authors:  C Rüegg; A Yilmaz; G Bieler; J Bamat; P Chaubert; F J Lejeune
Journal:  Nat Med       Date:  1998-04       Impact factor: 53.440

Review 6.  CXC chemokines in angiogenesis.

Authors:  J A Belperio; M P Keane; D A Arenberg; C L Addison; J E Ehlert; M D Burdick; R M Strieter
Journal:  J Leukoc Biol       Date:  2000-07       Impact factor: 4.962

7.  Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo.

Authors:  Han Xiao; Bo Huang; Ye Yuan; Dong Li; Ling-Fei Han; Yi Liu; Wei Gong; Feng-Hua Wu; Gui-Mei Zhang; Zuo-Hua Feng
Journal:  Clin Cancer Res       Date:  2007-02-26       Impact factor: 12.531

8.  A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity.

Authors:  Hiroshi Yoshida; Yu Katayose; Michiaki Unno; Masanori Suzuki; Hideaki Kodama; Shin-ichi Takemura; Ryutaro Asano; Hiroki Hayashi; Kuniharu Yamamoto; Seiki Matsuno; Toshio Kudo
Journal:  Cancer Immunol Immunother       Date:  2003-01-18       Impact factor: 6.968

Review 9.  Role of 4-1BB:4-1BB ligand in cancer immunotherapy.

Authors:  Adam T C Cheuk; Ghulam J Mufti; Barbara-ann Guinn
Journal:  Cancer Gene Ther       Date:  2004-03       Impact factor: 5.987

10.  Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.

Authors:  Yu-Fei He; Gui-Mei Zhang; Xiao-Hong Wang; Hui Zhang; Ye Yuan; Dong Li; Zuo-Hua Feng
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

View more
  1 in total

1.  Effect of pro-inflammatory mediators on membrane-associated mucins expressed by human ocular surface epithelial cells.

Authors:  Ann-Christin Albertsmeyer; Vinodh Kakkassery; Sandra Spurr-Michaud; Olivia Beeks; Ilene K Gipson
Journal:  Exp Eye Res       Date:  2009-12-29       Impact factor: 3.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.